Literature DB >> 25073403

Population pharmacokinetics of intravenous levofloxacin 500 mg/day dosage in infected patients.

Yuan Zhang, Li-Qin Zhu, Nan Wang, Xuequn Zhao, Wenjie Yang, Shuangmin Ji, Liying Sun.   

Abstract

The purpose of this study was to explore the population pharmacokinetic features of levofloxacin in Chinese infected patients. A total of 27 Chinese adult infected patients were treated with intravenous levofloxacin (500 mg/day). In total, 49 plasma samples of levofloxacin were collected immediately after intravenous dripping and before administration on the 3rd, 4th or 5th day. A nonlinear mixed effect model was used to model the population pharmacokinetic (PK) behavior of levofloxacin. The final population pharmacokinetic models were validated using the bootstrap method. Some covariates, including demographic characteristics and hematological and biological indicators, were analyzed. A structural model was developed based on a one-compartment model with intravenous infusion and first-order elimination. The typical population values for pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 5.84 L/h and 43.3L, respectively. The inter-individual variabilities of CL and V were 7.75% and 6.4%, respectively, while the intra-individual variability of observed concentrations was 0.06 microg/mL. The covariates of age and AST influenced the CL and V values determined by the final model. The present study developed population pharmacokinetic models for levofloxacin in infected Chinese patients. The results detailed here could provide a reference for individualized levofloxacin therapy in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25073403

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  3 in total

1.  PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Authors:  Catharine C Bulik; Justin C Bader; Li Zhang; Scott A Van Wart; Christopher M Rubino; Sujata M Bhavnani; Kim L Sweeney; Paul G Ambrose
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-28       Impact factor: 2.745

2.  Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.

Authors:  Liqin Zhu; Yuan Zhang; Jianwei Yang; Yongming Wang; Jianlei Zhang; Yuanyuan Zhao; Weilin Dong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-03-10       Impact factor: 2.441

3.  Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients.

Authors:  Eko Setiawan; Mohd-Hafiz Abdul-Aziz; Menino Osbert Cotta; Susaniwati Susaniwati; Heru Cahjono; Ika Yunita Sari; Tjipto Wibowo; Ferdy Royland Marpaung; Jason A Roberts
Journal:  Sci Rep       Date:  2022-05-27       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.